Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 37,428 | 43,648 | 32,607 | 56,196 | 42,046 |
| Cost of Goods | 14,161 | 17,047 | 11,605 | 18,667 | 18,009 |
| Gross Profit | 23,267 | 26,601 | 21,002 | 37,529 | 24,037 |
| Operating Expenses | 35,933 | 35,373 | 36,543 | 36,823 | 37,082 |
| Operating Income | -12,505 | -8,725 | -14,936 | 1,373 | -13,036 |
| Interest Expense | 6,661 | 2,149 | 2,498 | 1,419 | 1,410 |
| Other Income | -873 | 2,292 | -551 | 658 | -43 |
| Pre-tax Income | -20,039 | -8,582 | -17,985 | 612 | -14,489 |
| Net Income Continuous | -20,039 | -8,582 | -17,985 | 612 | -14,489 |
| Net Income | $-20,039 | $-8,582 | $-17,985 | $612 | $-14,489 |
| EPS Basic Total Ops | -0.10 | -0.04 | -0.09 | 0.01 | -0.08 |
| EPS Basic Continuous Ops | -0.10 | -0.04 | -0.09 | 0.01 | -0.08 |
| EPS Diluted Total Ops | -0.10 | -0.04 | -0.09 | 0.01 | -0.08 |
| EPS Diluted Continuous Ops | -0.10 | -0.04 | -0.09 | 0.01 | -0.08 |
| EPS Diluted Before Non-Recurring Items | -0.10 | -0.04 | -0.09 | 0.00 | -0.08 |
| EBITDA(a) | $-3,131 | $685 | $-5,561 | $10,777 | $-3,629 |